RELL

• Fourth quarter GAAP net income increased 244.4% to $3.7 million, or $0.25 per diluted share.
• Fiscal 2026 net sales increased 9.4% to $228.6 million, marking the second consecutive year of annual sales growth.
• Backlog reached $164.4 million, its highest level in three years, up 8.7% from the third quarter.
• Board declared a $0.06 per share quarterly cash dividend, payable August 26, 2026, to stockholders of record as of August 7, 2026.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• PMT net sales increased 9.7% year-over-year, driving overall growth; excluding Healthcare, PMT net sales rose 14.5%.
• Backlog grew 11.4% to $151.2 million at quarter end, the highest level in nearly three years.
• Gross margin improved to 31.9% of net sales, up from 31.0% in the prior year's third quarter.
• The Board declared a $0.06 per share quarterly cash dividend, payable May 27, 2026, to stockholders of record as of May 8, 2026.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• Green Energy Solutions (GES) sales increased 39.0% to $2.3 million, and Canvys sales rose 28.1% to $1.9 million.
• Operating income was $0.1 million, improving from an operating loss of $0.7 million in Q2 FY25; net loss narrowed to $0.1 million from $0.8 million.
• Backlog was $135.7 million at quarter end, up from $134.7 million at the end of Q1 FY26.
• Board declared a $0.06 per share quarterly cash dividend, payable February 25, 2026, to stockholders of record February 6, 2026.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• Net sales for Q1 FY26 (ended August 30, 2025) were $54.6 million, a 1.6% increase from $53.7 million in the prior year's first quarter.
• Diluted earnings per common share were $0.13, compared to $0.04 in the prior year's first quarter.
• Semiconductor wafer fab net sales increased 52.2% year-over-year; excluding Healthcare, net sales grew 6.8%.
• The Board declared a $0.06 per share quarterly cash dividend, payable November 26, 2025, to stockholders of record as of November 7, 2025.
• Backlog was $134.7 million at quarter end, versus $134.2 million at the end of fiscal 2025.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• Q4 FY25 net sales were $51.9 million, up 9.5% from $47.4 million in Q4 FY24.
• Q4 FY25 GAAP net income was $1.1 million ($0.08 diluted EPS); non-GAAP net income was $1.8 million ($0.12 diluted EPS).
• The company declared a $0.06 per share quarterly cash dividend, payable August 27, 2025, to shareholders of record August 8, 2025.
• Backlog was $134.2 million at end of Q4 FY25, roughly flat sequentially.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• GAAP net loss was $2.1 million ($0.15 diluted loss per share), including a $4.9 million loss on sale of Healthcare assets.
• Non-GAAP operating income was $2.2 million, up from $1.0 million in the prior year quarter.
• Cash and equivalents were $36.7 million with no debt as of March 1, 2025.
• Board declared a $0.06 per share quarterly cash dividend payable May 28, 2025.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• The purchase price is $8.2 million in cash, subject to a customary working capital adjustment.
• The transaction closed simultaneously with the execution of the agreement on January 24, 2025.
• Richardson Electronics entered into an exclusive 10-year global supply agreement to supply DirectMed with repaired Siemens CT X-ray tubes, and will continue manufacturing ALTA CT X-ray tubes for DirectMed for approximately 12 to 18 months.
• The remaining Richardson Healthcare assets and operations will be consolidated into the Company's PMT reportable segment, and the sale is intended to support the company's Green Energy Solutions business.

1.01 Entry into a Material Definitive Agreement · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Q2 FY25 net sales were $49.5 million, up 12.1% from $44.1 million in Q2 FY24.
• Net loss narrowed to $0.8 million ($0.05 per diluted share) from $1.8 million ($0.13 per diluted share) in Q2 FY24.
• Gross margin improved to 31.0% from 28.4% YoY; operating loss improved to $0.7 million from $2.0 million.
• Company ended Q2 with $26.6 million cash, no debt, and declared a $0.06 per share quarterly dividend payable Feb 26, 2025.
• Management expects YoY sales growth and higher profitability for FY25.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits